Ranolazine for the treatment of stable angina
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000640
English, French
Authors' objectives:
To summarize the available information on the use of ranolazine (Trade Name Ranexa, manufactured by CV Therapeutics, Inc.) for the treatment of stable angina.
Authors' recommendations:
Ranozaline has been investigated as monotherapy and as combination therapy in patients with stable angina. Both trials demonstrate significant anti-anginal efficacy, but several questions regarding the dose, target population, and safety remain unanswered. The lack of dose-response data and the evidence of a prolonged QTc interval with higher doses warrant further investigation. The ideal patient population must be defined as to whether ranolazine should be restricted to a particular group of patients. Ranolazine's tolerability and efficacy profile at therapeutic doses over the longer term requires further study, possibly with other anti-anginal agents.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Angina Pectoris
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.